Pharmacoeconomics analysis in a pediatric population

Area of Science:

• Health Economics
• Pharmacoeconomics
• Surgical Outcomes

Background:

• Pharmacoeconomics is crucial in healthcare but faces methodological challenges.
• Pharmacoeconomic analysis can evaluate the benefits of pharmacologic hemostasis.

Purpose of the Study:

• To review pharmacoeconomic analysis methods and their concerns.
• To assess pharmacoeconomic studies of pharmacologic hemostasis, focusing on pediatric open-heart surgery.

Main Methods:

• Review of pharmacoeconomic methodologies.
• Analysis of a randomized trial comparing high-dose aprotinin, low-dose aprotinin, and placebo in pediatric repeat open-heart surgery.
• Evaluation using cost-benefit, cost-effectiveness (decision tree), and cost-effective ratios.

Main Results:

• Low-dose aprotinin demonstrated superior cost-benefit compared to high-dose aprotinin.
• High-dose aprotinin was more cost-effective than low-dose aprotinin based on cost-effectiveness analysis and ratios.
• Aprotinin, in both doses, was found to be preferable to placebo.

Conclusions:

• Aprotinin is both cost-beneficial and cost-effective in pediatric repeat open-heart operations.
• The findings support the use of aprotinin in this patient population.